Macquarie Group LTD Biotechnology

Macquarie Group LTD

$90.3 Billion
Q3 2024

Stock List

Stock	Market Cap.	Holding Value (Reported)	# of Shares.	Last Trade	Trade History
TBPH Theravance Biopharma, Inc.	$614M	$1.68 Million 0.0% of portfolio	208,783	Q3 2024 Reduced 0.34%
RGNX Regenxbio Inc.	$354M	$1.56 Million 0.0% of portfolio	149,000	Q4 2022 Reduced 0.22%
DAWN Day One Biopharmaceuticals, Inc.	$896M	$1.53 Million 0.0% of portfolio	110,000	Q3 2024 Reduced 0.55%
ACAD Acadia Pharmaceuticals Inc	$2.83B	$1.43 Million 0.0% of portfolio	92,648	Q2 2024 Reduced 80.18%
MGNX Macrogenics Inc	$214M	$1.38 Million 0.0% of portfolio	420,000	Q4 2022 Reduced 0.12%
RPRX Royalty Pharma PLC	$11.4B	$1.32 Million 0.0% of portfolio	46,788	Q2 2024 Added 2.32%
PRQR Pro Qr Therapeutics N.V.	$186M	$1.13 Million 0.0% of portfolio	620,000	Q1 2021 New
RCKT Rocket Pharmaceuticals, Inc.	$935M	$1.07 Million 0.0% of portfolio	58,000	Q4 2022 Reduced 0.54%
VTYX Ventyx Biosciences, Inc.	$137M	$937,000 0.0% of portfolio	430,000	Q1 2024 New
CHRS Coherus Bio Sciences, Inc.	$126M	$935,000 0.0% of portfolio	899,999	Q1 2024 Added 38.46%
WVE Wave Life Sciences Ltd.	$1.13B	$672,000 0.0% of portfolio	81,955	Q1 2021 New
ALT Altimmune, Inc.	$355M	$614,000 0.0% of portfolio	100,000	Q2 2024 Added 124.85%
CLLS Cellectis S.A.	$96.9M	$480,000 0.0% of portfolio	226,875	Q3 2020 Added 3.28%
KPTI Karyopharm Therapeutics Inc.	$66.2M	$415,000 0.0% of portfolio	500,000	Q3 2024 Reduced 1.12%
NTLA Intellia Therapeutics, Inc.	$973M	$411,000 0.0% of portfolio	20,000	Q4 2022 Reduced 2.34%
ALLO Allogene Therapeutics, Inc.	$311M	$410,000 0.0% of portfolio	146,779	Q4 2022 Reduced 0.4%
ARGX Argenx Se	$35.9B	$381,000 0.0% of portfolio	704	Q4 2023 Added 163.67%
SGMO Sangamo Therapeutics, Inc	$211M	$344,000 0.0% of portfolio	400,000	Q3 2024 Reduced 1.88%
LEGN Legend Biotech Corp	$5.62B	$335,000 0.0% of portfolio	6,887	Q4 2023 Added 22.89%
NKTR Nektar Therapeutics	$219M	$333,000 0.0% of portfolio	256,385	Q4 2022 Reduced 0.99%
MRSN Mersana Therapeutics, Inc.	$132M	$283,000 0.0% of portfolio	150,000	Q4 2022 Reduced 2.47%
AVIR Atea Pharmaceuticals, Inc.	$283M	$234,000 0.0% of portfolio	70,000	Q4 2022 Reduced 2.1%
NXTC Next Cure, Inc.	$26.4M	$205,000 0.0% of portfolio	150,000	Q1 2022 Reduced 0.16%
PBYI Puma Biotechnology, Inc.	$177M	$156,000 0.0% of portfolio	61,255	Q2 2024 Reduced 2.44%
AMRN Amarin Corp Plcuk	$214M	$119,000 0.0% of portfolio	190,000	Q3 2020 New
XOMA Xoma Corp	$301M	$91,000 0.0% of portfolio	3,466	Q2 2020 Reduced 36.29%
VYGR Voyager Therapeutics, Inc.	$233M	$33,000 0.0% of portfolio	5,700	Q1 2022 Reduced 7.54%
NVO Novo Nordisk A S	$188B	$12,000 0.0% of portfolio	105	Q3 2024 Reduced 40.34%
AUPH Aurinia Pharmaceuticals Inc.	$1.19B	$10,000 0.0% of portfolio	1,473	Q3 2024 Reduced 93.29%
GMAB Genmab A/S	$14.6B	$5,000 0.0% of portfolio	230	Q3 2024 Added 5.99%
TCRX T Scan Therapeutics, Inc.	$57M	$5,000 0.0% of portfolio	1,047	Q3 2024 New

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.